Long-term outcomes for children with an incidentally discovered Chiari malformation type 1: what is the clinical significance?

Author(s):  
Laurence Davidson ◽  
Tiffany N. Phan ◽  
John S. Myseros ◽  
Suresh N. Magge ◽  
Chima Oluigbo ◽  
...  
2021 ◽  
pp. 1-7
Author(s):  
Recep Basaran ◽  
Caglar Bozdogan ◽  
Mehmet Senol ◽  
Dogan Gundogan ◽  
Nejat Isik

Circulation ◽  
2008 ◽  
Vol 118 (suppl_18) ◽  
Author(s):  
Manuel A Gonzalez ◽  
Dana Eilen ◽  
Rana A Marzouq ◽  
Saed Awadallah ◽  
Hiren R Patel ◽  
...  

Introduction: The universal classification (UC) of AMI aims to facilitate cross-study analysis, yet the long-term outcomes using UC are largely unknown. Hypothesis: We tested the hypothesis that the long-term outcome of patients with AMI is better predicted by UC than ST segment classification. Methods: We conducted a prospective study of 348 consecutive patients with AMI with mean follow-up of 30.6 months. The primary outcome was the major adverse cardiovascular events (MACE) [composite of all causes of mortality, recurrent AMI, and stroke]. Multivariate and survival analysis of MACE was performed. Results: The study population was STEMI=168, NSTEMI=180, Type 1=278, Type 2=55, Type 3=5, Type 4a=2, Type 4b=5, and Type 5=3. During follow-up 80 patients died, 31 had an AMI, and 7 had a stroke. UC correlates with the ST segment classification (p<0.005). MACE free survival was different for Type 1 and Type 2 (p=0.043), but not for STEMI and NSTEMI. There was a positive association between MACE and the quartile of peak Troponin, number of cardiovascular risk factors, and number of vascular beds affected, and an inverse relationship with the utilization of discharge cardiovascular protective medications (all p≤0.01). No such inverse relationship existed for Type 2. Conclusions: UC of AMI is a better long-term predictor of MACE. The quartile of peak Troponin levels, cardiovascular risk factors, and number of vascular beds affected are independent predictors of MACE, while cardiac medications protect against MACE, except in Type 2 patients.


2017 ◽  
Vol 126 (2) ◽  
pp. 654-657
Author(s):  
Ori Barzilai ◽  
Jonathan Roth ◽  
Akiva Korn ◽  
Shlomi Constantini

HIV Medicine ◽  
2021 ◽  
Author(s):  
Allison Silverstein ◽  
William Kamiyango ◽  
Jimmy Villiera ◽  
Erin C. Peckham‐Gregory ◽  
Casey L. McAtee ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document